October 18, 2010 | HUYA Bioscience International and Quintiles have announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA. HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge to the U.S. development process and worldwide pharmaceutical markets. HUYA licensed all ex-China rights to HBI-8000 from Chipscreen Bioscience. HBI-8000 has now entered a Phase I clinical trial in the U.S. under an IND application with the FDA. This trial is designed to assess safety, tolerability and antitumor activity of HBI-8000 in patients with advanced solid tumors and lymphomas. Quintiles